Skip to content

CA Intermediate · Financial Management and Strategic Management · Strategic Analysis: Internal Environment

Mehra Pharma has a strong R&D lab, but its 5 plants run at only 55% capacity, distribution partners complain of late deliveries, and employee attrition is high. Management says it must first diagnose which internal capabilities are truly distinctive before choosing a strategy. Which approach best fits that diagnosis?

Test R&D against the tests of value, rarity, inimitability and non-substitutability before calling it a core competence, and treat low utilisation, late deliveries and attrition as gaps to fix. Internal analysis must separate distinctive strengths from weaknesses rather than treat every area alike.

  1. ATreat R&D as a core competence only if it also meets the tests of being valuable, rare, hard to imitate and non-substitutable, and treat the other weak areas as capability gaps to correctCorrect
  2. BTreat all areas equally as strengths because the firm has invested in each
  3. CTreat the underutilised plants as the core competence because they offer scale
  4. DDrop the internal review and rely on the industry's external opportunities

Explanation

Core competences are identified by testing capabilities against criteria such as value, rarity, inimitability and non-substitutability. Strong R&D may qualify, while low utilisation, late deliveries and attrition are weaknesses. Treating all areas alike or ignoring internal analysis fails to separate competences from gaps.

Did you get it right without looking?

One question tells you little. A timed set on Strategic Analysis: Internal Environment shows your real accuracy, how long you take and where you lose marks.

More Strategic Analysis: Internal Environment questions